BioCentury
ARTICLE | Clinical News

GI-5005: Additional Phase IIb data

April 19, 2010 7:00 AM UTC

Additional data from a Phase IIb trial in 140 patients with chronic HCV genotype 1 showed that significantly more patients receiving GI-5005 plus standard care with Copegus ribavirin and Pegasys peg...